… hope of drugging KRAS. In this review, the latest research progress on KRAS, the characteristics
of KRAS mutations, the relationship between the KRAS mutations and tumour immunity, …

… , there were trends toward greater improvement in OS, PFS, and ORR compared with other
KRAS mutations [45]. A phase 1/1b study evaluated the efficacy and safety of trametinib plus …

… cell lines, by measuring the reduction of phospho-MEK adaptive induction after … MEK
inhibitors led to enhanced antiproliferative activity and MAPK pathway suppression in KRAS-mutant …

… We find that RAF dimer inhibitor and MEK inhibitor show synergistic effect both in vitro and
in vivo in K-RAS mutant tumors and correlate the synergy with the PD effect. These findings …

… Using synthetic lethal shRNA screening in KRAS mutant cancer models, BCL-XL was
found … In this study of KRAS-mutant lung cancer models, combining MEK inhibition with …

… , wherein tumor inhibition function and … KRAS-MEK inhibitors in combination with radiotherapy
can enhance antitumor immunity, providing new therapeutic strategies for KRAS-mutated …

… rationally combine these two modalities to treat KRAS mutant lung cancers. In addition to
the essential role of MEKis in RAS-MEK-ERK signaling suppression during the tumorigenesis …

… a promising combinatorial therapy with MEK inhibitors to treat KRAS mutant lung cancers. …
to understand the mechanisms of MEK inhibitor resistance in KRAS mutant lung cancers and …

… inhibitor JQ1 suppressed interferon-stimulated gene (ISG) expression and in combination
with MEK inhibitors … the limited response to MEK inhibitors in KRAS-mutant colorectal cancer, …

… In support of this, a recent study using KRAS mutation-driven mouse models demonstrated
higher efficacy of the MEK inhibitor selumetinib in KRAS G12C tumors compared with …